Colorado SLOS Cholesterol and Antioxidant Study
Also known as: Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS), Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome, DEKAS Plus antioxidant arm, cholesterol suspension / eggs / Slo-lesterol arm, Smith-Lemli-Opitz syndrome cholesterol antioxidant study, NCT01773278
Institution-led study
Academic Phase 2 study treating biochemically confirmed Smith-Lemli-Opitz syndrome with cholesterol supplementation plus antioxidant medication, while monitoring sterol biochemistry and serial clinical measures including brainstem audiometry. Hearing loss is part of the syndromic phenotype and monitoring plan, but the cholesterol and antioxidant components are one systemic SLOS treatment protocol rather than separate hearing-loss pipeline programs.
Promoted as a verified registry-backed academic SLOS treatment-protocol record while preserving the stale-status caveat. ClinicalTrials.gov and registry mirrors describe one University of Colorado study treating Smith-Lemli-Opitz syndrome with cholesterol supplementation and antioxidant medication, with hearing monitored as part of the syndromic phenotype; these protocol components should not appear as separate hearing-loss pipeline programs.